MarketPeel
Insider Trading Intelligence
Pricing
…
RF

Rhonda Farnum

TBPH
SVP, COMM & MEDICAL AFFAIRS · THERAVANCE BIOPHARMA, INC. · CIK 0001898490
FILING MIX · LIFETIME13%/87%
BUYS
6
SELLS
42
TOTAL VALUE
$4.00M
COMPANIES
1
ACTIVE SINCE
Dec 2021
HOLDINGS NOW
242,442
AVG SELL PX
$12.25
TRADE KIND
SHOWING 48 / 48
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
21 backtested trades · 8 horizons · 26 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Rhonda Farnum, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d21+47.62%+1.14%+0.52%+0.62%+0.07%—
14d21+47.62%+1.05%-0.10%+1.15%-1.68%—
30d21+42.86%+3.35%+2.53%+0.83%-0.20%—
60d21+33.33%+7.01%+3.36%+3.65%+3.29%—
90d21+42.86%+2.88%+4.87%-1.99%-0.38%—
180d21(3 pending)+55.56%+16.05%+9.63%+12.64%+4.05%—
1y21(9 pending)+33.33%+29.95%+19.74%+8.93%+11.35%—
2y21(14 pending)+42.86%+32.60%+40.76%-8.16%-26.28%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TBPH · 242,442 shares · as of Jun 15, 2026
093,510187,019280,529374,03820222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 6 buys / 42 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
3,329$16.39$54.6K242,442Jun 15, 2026Jun 17, 2026 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
3,328$16.38$54.5K239,114Jun 15, 2026Jun 17, 2026 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
6,657$16.39$109.1K232,457Jun 15, 2026Jun 17, 2026 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
5,678$16.55$94.0K245,771May 20, 2026May 22, 2026 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
18,750——251,449Apr 1, 2026Apr 3, 2026 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
7,766$13.92$108.1K232,699Mar 16, 2026Mar 18, 2026 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
15,534$14.00$217.5K240,465Mar 16, 2026Mar 18, 2026 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
7,767$13.92$108.1K255,999Mar 16, 2026Mar 18, 2026 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
13,929$19.66$273.8K263,766Feb 20, 2026Feb 24, 2026 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
7,766$18.75$145.6K293,229Dec 3, 2025Dec 5, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
15,534$18.75$291.3K277,695Dec 3, 2025Dec 5, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
7,767$18.75$145.6K300,995Dec 3, 2025Dec 5, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
9,060$17.90$162.2K308,762Nov 20, 2025Nov 24, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
9,096$13.39$121.8K317,822Aug 20, 2025Aug 22, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
4,000$11.39$45.6K326,918Jul 14, 2025Jul 16, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
5,318$11.39$60.5K330,918Jul 14, 2025Jul 16, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
682$11.39$7.8K336,236Jul 14, 2025Jul 16, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
24,000$11.00$264.0K336,918Jun 2, 2025Jun 4, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
9,120$9.45$86.2K360,918May 20, 2025May 22, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
4,000$9.00$36.0K370,038Apr 21, 2025Apr 23, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
75,000——374,038Feb 28, 2025Mar 4, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
15,810$9.66$152.7K299,038Feb 20, 2025Feb 24, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
5,283——314,848Feb 10, 2025Feb 24, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
4,000$9.00$36.0K309,565Jan 21, 2025Jan 23, 2025 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
9,178$9.97$91.5K313,565Nov 20, 2024Nov 22, 2024 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
4,000$9.00$36.0K322,743Nov 11, 2024Nov 13, 2024 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
9,222$8.22$75.8K326,743Aug 20, 2024Aug 22, 2024 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
4,000$9.00$36.0K335,965Jul 10, 2024Jul 12, 2024 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
9,268$9.10$84.3K339,965May 20, 2024May 22, 2024 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
37,500——349,233Apr 2, 2024Apr 4, 2024 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
1,254$8.71$10.9K311,733Feb 22, 2024Feb 22, 2024 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
18,219$8.92$162.5K312,987Feb 20, 2024Feb 22, 2024 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
1,378$10.29$14.2K331,206Nov 21, 2023Nov 22, 2023 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
7,982$10.37$82.8K332,584Nov 20, 2023Nov 22, 2023 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
1,807$9.47$17.1K340,566Aug 22, 2023Aug 24, 2023 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
10,460$9.70$101.5K342,373Aug 20, 2023Aug 22, 2023 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
1,790$11.13$19.9K352,833Jun 8, 2023Jun 12, 2023 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
5,567$11.21$62.4K354,623May 20, 2023May 23, 2023 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
4,000$10.20$40.8K360,190Mar 9, 2023Mar 13, 2023 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
75,000——364,190Mar 1, 2023Mar 3, 2023 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
7,119$10.44$74.3K289,190Feb 20, 2023Feb 22, 2023 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
23,268$10.85$252.5K296,309Nov 20, 2022Nov 22, 2022 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
10,413$9.34$97.3K319,577Aug 19, 2022Aug 23, 2022 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
1,081$8.93$9.7K329,990May 23, 2022May 24, 2022 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
2,200$8.74$19.2K331,071May 20, 2022May 24, 2022 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
2,356$10.16$23.9K333,271Feb 28, 2022Mar 2, 2022 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, COMM & MEDICAL AFFAIRS
11,824$9.61$113.6K335,627Feb 18, 2022Feb 23, 2022 ↗View →
TBPH
THERAVANCE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
27,500——347,451Dec 14, 2021Dec 16, 2021 ↗View →
Other insiders · TBPH
Loading peer insiders…
About this filer
CIK 0001898490
ROLE
SVP, COMM & MEDICAL AFFAIRS
PRIMARY
TBPH
COMPANIES
1
ACTIVE SINCE
Dec 2021
MARKETPEEL · /INSIDER/0001898490DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback